LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Stevanato Group SpA

Geschlossen

BrancheGesundheitswesen

15.6 0.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

15.05

Max

15.74

Schlüsselkennzahlen

By Trading Economics

Einkommen

10M

49M

Verkäufe

23M

303M

KGV

Branchendurchschnitt

26.833

121.746

EPS

0.162

Dividendenrendite

0.35

Gewinnspanne

16.205

Angestellte

5,521

EBITDA

10M

73M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+48.01% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.35%

2.26%

Nächstes Ergebnis

5. März 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.3B

4.4B

Vorheriger Eröffnungskurs

15.08

Vorheriger Schlusskurs

15.6

Nachrichtenstimmung

By Acuity

50%

50%

160 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Stevanato Group SpA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Feb. 2026, 23:57 UTC

Heiße Aktien

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12. Feb. 2026, 23:35 UTC

Ergebnisse
Wichtige Markttreiber

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12. Feb. 2026, 23:28 UTC

Ergebnisse

Applied Materials Profit Rises on Soaring AI Demand -- Update

12. Feb. 2026, 21:47 UTC

Ergebnisse

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13. Feb. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12. Feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12. Feb. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12. Feb. 2026, 23:33 UTC

Ergebnisse

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12. Feb. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12. Feb. 2026, 22:55 UTC

Ergebnisse
Heiße Aktien

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12. Feb. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12. Feb. 2026, 22:23 UTC

Ergebnisse

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12. Feb. 2026, 21:57 UTC

Ergebnisse

XP 4Q Rev BRL4.95B >XP

12. Feb. 2026, 21:52 UTC

Ergebnisse

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. Feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Feb. 2026, 21:47 UTC

Ergebnisse

Morningstar 4Q Rev $641M >MORN

12. Feb. 2026, 21:39 UTC

Ergebnisse

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. Feb. 2026, 21:38 UTC

Ergebnisse

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Peer-Vergleich

Kursveränderung

Stevanato Group SpA Prognose

Kursziel

By TipRanks

48.01% Vorteil

12-Monats-Prognose

Durchschnitt 23.83 USD  48.01%

Hoch 30 USD

Tief 17.5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Stevanato Group SpA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

21.56 / 22.61Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

160 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat